This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Control of Epidemic Influenza Through a School-based Influenza Vaccination Program (CEI)

This study has been completed.
Sponsor:
Collaborators:
Scott and White Hospital & Clinic
Novartis
Sanofi Pasteur, a Sanofi Company
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Pedro Piedra, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00138294
First received: August 26, 2005
Last updated: May 16, 2017
Last verified: May 2017
August 26, 2005
May 16, 2017
October 1998
June 2010   (Final data collection date for primary outcome measure)
  • MAARI Rate During the Epidemic Period (2007-2008) [ Time Frame: 12/16/2007 to 3/29/2008 (15 weeks) ]
    The rate of MAARI (MAARIs/1000 persons-week) were compared between the intervention and comparison cities during the epidemic period (irrespective of the vaccination status). This data was obtained from the SWHP database.
  • MAARI Rate During the Epidemic Period (2008-2009) [ Time Frame: 1/4/2009 to 3/21/2009 (11 weeks) ]
    The rate of MAARI (MAARIs/1000 persons-week) were compared between the intervention and comparison cities during the epidemic period (irrespective of the vaccination status). This data was obtained from the SWHP database.
  • MAARI Rate During the Epidemic and Pandemic Period (2009-2010) [ Time Frame: 8/25/09 to 4/3/10 (32 weeks) ]
    The rate of MAARI (MAARIs/1000 persons-week) were compared between the intervention and comparison cities during the epidemic period (irrespective of the vaccination status). This data was obtained from the SWHP database.
Not Provided
Complete list of historical versions of study NCT00138294 on ClinicalTrials.gov Archive Site
Proportion of SAEs Detected in LAIV Recipients [ Time Frame: pre-, post- influenza vaccination ]
Serious adverse events (SAEs) within 42 days post-LAIV vaccination will be captured in seasonal and pandemic vaccinated study subjects.
Not Provided
Not Provided
Not Provided
 
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
Phase 4, School-based, Open-labeled Research Trial for Control of Epidemic Influenza Through a School-based Influenza Vaccination Program in Central Texas.
The main purpose of this study is to learn if influenza vaccines (live attenuated and inactivated influenza vaccines), when given to school-aged children 4 to 18 years of age, can stop or lessen the influenza (flu) outbreak in the community. Another purpose is to show that vaccination of these children will significantly reduce breathing problems (in the vaccinated children and unvaccinated people they come in contact with in the community) that require a visit to the doctor for treatment. Another purpose is to continue to collect safety and flu protection information on live attenuated influenza vaccine (LAIV or FluMist) given to children. The study investigators believe that vaccination of healthy school-aged children is an effective plan for preventing many people in the community from catching the flu. Children will take part in the study for 5 to 10 months.

This study was conducted in three phases. The first phase spanned from 1998-2003 (PubMed ID:14706961; PubMed ID: 12915495) and the second phase spanned from 2003-2007 (PubMedID: 18401289; PubMed ID: 17698577). The final phase of the study spanned 2007-2011 and is the scope of this submission.

The goal of the final phase is to control epidemic influenza through active immunization of healthy school-aged children with the cold-adapted, trivalent, live, attenuated influenza vaccine (LAIV) and at-risk children with the inactivated influenza vaccine (IIV) through a school-based vaccination program.

The hypothesis is that universal vaccination of healthy school-aged children is an alternative and effective strategy for the control of epidemic influenza, and will serve as a model for the control of pandemic influenza and biodefense. The specific aims of the study are: to control the spread of influenza to susceptible adults 35 years of age or older by vaccination of school-aged children 4-18 years of age; to control the spread of influenza to susceptible children and young adults less than 35 years of age by vaccination of school-aged children 4-18 years of age; to develop a school-based vaccination program for rapid and timely delivery of LAIV and IIV to children 4-18 years of age; to demonstrate in school-aged children the direct and total effectiveness of influenza vaccines to reduce the rates of medically attended acute respiratory illness (MAARI) in LAIV and IIV recipients during influenza epidemics; and to capture safety information on LAIV post-licensure.

This is an open-label, up to four year community-based study. In each of the first three study years, school-aged children (4 through 18 years of age) who receive medical care at the Scott & White Clinics (SWCs), Temple-Belton area, Texas, will be asked to participate in this study. Study participants will receive LAIV or IIV according to their health status. Other children from Temple-Belton area who do not receive medical care at the SWC will be invited to participate in the study and may receive LAIV or IIV. A comparable population enrolled in the SWCs in Waco/McLennan County area and Bryan/College Station will serve as comparison groups.

In the fourth and final year of the study, LAIV will not be provided through the study. However, influenza surveillance will continue and MAARI data will be collected to assess continued protective benefit of influenza vaccines. The final year will also be devoted to completion of data analysis and preparation of manuscripts.

Children 4 years through 8 years who have not previously been vaccinated with an influenza vaccine will be offered a second dose 4 to 6 weeks after the first dose. The influenza vaccines will contain the three influenza virus strains chosen by the FDA. Each subject will receive by nasal spray a 0.2 ml dose (0.1 ml in each nostril) of the LAIV or 0.5 ml intramuscularly.

The duration of each study year is approximately five to ten months, from the time of enrollment (August to January, at the discretion of the investigators) depending on vaccine availability and the timing of influenza activity, to the end of the influenza season (May).

Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Influenza
Biological: live attenuated and inactivated influenza vaccines
Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
Other Names:
  • FluMist
  • Fluzone
  • Experimental: Intervention Cities
    Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
    Intervention: Biological: live attenuated and inactivated influenza vaccines
  • Active Comparator: Comparison Cities
    Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
    Intervention: Biological: live attenuated and inactivated influenza vaccines

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29255
June 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • signed informed consent form by adult participant or parent/ legal guardian who are able to understand and comply with the protocol and assent when appropriate (usually age greater than or equal to 7 years)
  • healthy subject, 4 through 18 years of age and none of the exclusion criteria

Exclusion Criteria:

  • history of hypersensitivity, especially anaphylactic reaction, to any components of FluMist™, including eggs or egg products
  • on aspirin therapy or aspirin-containing therapy
  • history of Guillain-Barré syndrome
  • known or suspected immune deficiency diseases such as combined immunodeficiency, agammaglobulinemia, and thymic abnormalities and conditions such as human immunodeficiency virus infection, malignancy, leukemia or lymphoma
  • on immunosuppressive therapies such as systemic corticosteroids, alkylating drugs, antimetabolites, or radiation
  • close contact within 21 days after vaccination with immunocompromised individuals
  • history of asthma or reactive airway disease
  • history of chronic or underlying diseases for which the licensed inactivated flu vaccine (IIV-T) is recommended such as chronic disorders of the cardiovascular and pulmonary systems, or chronic conditions such as metabolic diseases, renal dysfunction or hemoglobinopathies that required medical follow-up or hospitalization during the preceding year
  • concurrent use with an anti-influenza compound
  • pregnant or plans to become pregnant within 42 days after vaccination
  • nursing mother and
  • any condition which, in the opinion of the investigator, interferes with evaluation of the vaccine
Sexes Eligible for Study: All
4 Years to 18 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00138294
BCM H-21853
Flu-035-09 ( Other Identifier: MedImmune Inc )
BCM H-21853 ( Other Identifier: Baylor College of Medicine )
SW070912 ( Other Identifier: Scott and White )
R01AI041050 ( U.S. NIH Grant/Contract )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Plan to Share IPD: No
Pedro Piedra, Baylor College of Medicine
Baylor College of Medicine
  • Scott and White Hospital & Clinic
  • Novartis
  • Sanofi Pasteur, a Sanofi Company
  • National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Pedro A Piedra, MD Baylor College of Medicine
Baylor College of Medicine
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP